GlaxoSmithKline shares have performed well this year and are up over 15%, but they are still well down from their highs of around 1,800 in 2020 and 2022. In this analysis, I look at why GSK shares are so low, if they will keep on falling and whether or not they are worth a buy for recovery.
Haleon demerger
Two major pharma companies occupy the to...
Get unlimited access to the Good Money Guide expert analysis
Become a better, more informed investor with Good Money Guide. Our expert exclusive analysis provides the sort of information that everyone, from first-time investors to experienced professional traders, can learn to profit from.
Monthly
Premium
£
4
99
Monthly -
Broker Comparison
-
Expert Market Analysis
-
Buy & Sell Ratings
-
Investing Indicators
-
Educational Courses
-
Exclusive Event Invites
Pay Monthly
Cancel anytime
Yearly
Premium
£
49
Yearly
-
Save 15%
-
14-Day Money Back Guarantee
-
Broker Comparison
-
Expert Market Analysis
-
Buy & Sell Ratings
-
Investing Indicators
-
Educational Courses
-
Exclusive Event Invites
Pay Yearly
Cancel anytime
Save 15%